Mycobacterium tuberculosis Specific CD8+ T Cells Rapidly Decline with Antituberculosis Treatment

Simple item page
dc.contributor.authorNyendak, Melissa R.
dc.contributor.authorPark, Byung
dc.contributor.authorNull, Megan D.
dc.contributor.authorBaseke, Joy
dc.contributor.authorSwarbrick, Gwendolyn
dc.contributor.authorMayanja-Kizza4, Harriet
dc.contributor.authorNsereko, Mary
dc.contributor.authorJohnson, Denise F.
dc.contributor.authorGitta, Phineas
dc.contributor.authorOkwera, Alphonse
dc.contributor.authorGoldberg, Stefan
dc.contributor.authorBozeman, Lorna
dc.contributor.authorJohnson, John L.
dc.contributor.authorBoom, W. Henry
dc.contributor.authorLewinsohn, Deborah A.
dc.contributor.authorLewinsohn, David M.
dc.contributor.authorthe Tuberculosis Research Unit and the Tuberculosis Trials Consortium
dc.date.accessioned2022-05-25T09:54:53Z
dc.date.available2022-05-25T09:54:53Z
dc.date.issued2013
dc.description.abstractBiomarkers associated with response to therapy in tuberculosis could have broad clinical utility. We postulated that the frequency of Mycobacterium tuberculosis (Mtb) specific CD8+ T cells, by virtue of detecting intracellular infection, could be a surrogate marker of response to therapy and would decrease during effective antituberculosis treatment. We sought to determine the relationship of Mtb specific CD4+ T cells and CD8+ T cells with duration of antituberculosis treatment. We performed a prospective cohort study, enrolling between June 2008 and August 2010, of HIV-uninfected Ugandan adults (n = 50) with acid-fast bacillus smear-positive, culture confirmed pulmonary TB at the onset of antituberculosis treatment and the Mtb specific CD4+ and CD8+ T cell responses to ESAT-6 and CFP-10 were measured by IFN-γ ELISPOT at enrollment, week 8 and 24.There was a significant difference in the Mtb specific CD8+ T response, but not the CD4+ T cell response, over 24 weeks of antituberculosis treatment (p<0.0001), with an early difference observed at 8 weeks of therapy (p = 0.023). At 24 weeks, the estimated Mtb specific CD8+ T cell response decreased by 58%. In contrast, there was no significant difference in the Mtb specific CD4+ T cell during the treatment. The Mtb specific CD4+ T cell response, but not the CD8+ response, was negatively impacted by the body mass index.Our data provide evidence that the Mtb specific CD8+ T cell response declines with antituberculosis treatment and could be a surrogate marker of response to therapy. Additional research is needed to determine if the Mtb specific CD8+ T cell response can detect early treatment failure, relapse, or to predict disease progression.en_US
dc.identifier.citationNyendak, M. R., Park, B., Null, M. D., Baseke, J., Swarbrick, G., Mayanja-Kizza, H., ... & Tuberculosis Research Unit and the Tuberculosis Trials Consortium. (2013). Mycobacterium tuberculosis specific CD8+ T cells rapidly decline with antituberculosis treatment. PLoS One, 8(12), e81564.https://doi.org/10.1371/journal.pone.0081564en_US
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3311
dc.language.isoenen_US
dc.publisherPLoS Oneen_US
dc.titleMycobacterium tuberculosis Specific CD8+ T Cells Rapidly Decline with Antituberculosis Treatmenten_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Mycobacterium tuberculosis Specific CD8+ T Cells Rapidly Decline with Antituberculosis Treatment.pdf
Size:
654.25 KB
Format:
Adobe Portable Document Format
Description:
Mycobacterium tuberculosis Specific CD8+ T Cells Rapidly Decline with Antituberculosis Treatment
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences